Why Zydus Lifesciences is Down Today: Stock Decline Analysis
Why Zydus Lifesciences is down today is a question many investors are asking as the pharma giant faces pressure on December 9, 2025. The stock is trading at around Rs 936.45, showing a decline of 0.66% from the previous close of Rs 942.70.
This marks a continuation of weakness, with the stock down approximately 4.24% over the past two trading sessions. The company with a market cap of Rs 93,800 crore is facing technical selling pressure and sector-wide headwinds.
Trading volume remains moderate at around 3.71 lakh shares, which is below the five day average. The stock is currently trading below its key moving averages including the 5 day at Rs 945, 20 day at Rs 950, and 50 day at Rs 960, indicating clear technical weakness in the near term.
Also Read: Why Dr. Reddy’s Laboratories is Down Today: Trade Tensions and Regulatory Setbacks Hit Stock
The recent fall in Zydus Lifesciences share price is primarily driven by technical factors and broader market dynamics. The stock has underperformed its pharma sector peers by around 2.74% in the last two days.
One major red flag is the surge in open interest by 35.38% to 20,417 contracts. This indicates that traders are taking fresh short positions or placing bearish bets on the stock.
At the same time, delivery volume has dropped by 35.19% from the five day average. This shows reduced investor conviction and suggests that many traders are booking profits rather than holding for the long term.
From a technical perspective, Zydus is testing critical support near the Rs 930 level after failing to hold above Rs 950. The stock’s inability to maintain momentum above key moving averages has triggered algorithmic selling and stop loss orders.
The 52 week low stands at Rs 795, which provides a strong support base. However, immediate resistance is seen at Rs 950 to Rs 960 levels.
Traders should watch the Rs 930 support carefully as a break below this level could trigger further downside towards Rs 920 or lower levels in the short term.
The US market performance presents a mixed picture for Zydus Lifesciences. According to the latest IQVIA data for October 2025, the company saw a notable month on month sales increase of USD 10 million in the trailing three months.
This growth was driven by strong performance in generic versions of drugs like Myrbetriq used for overactive bladder and Entresto for heart failure treatment. However, the overall industry wide T3M US sales dipped slightly to USD 3.98 billion.
This decline was due to competitive pressures and pricing erosion affecting the entire generic drug sector in America.
On December 4, 2025, Zydus received an Establishment Inspection Report from the USFDA for its Jarod injectable facility. The inspection conducted from August 25 to September 5, 2025 resulted in a VAI or Voluntary Action Indicated classification.
This is generally considered a positive outcome as it means no major Form 483 issues were found. However, the inspection did yield four observations during the same period. When this news was announced, the stock dipped by 0.45% to Rs 1,009.60 on that day.
Some investors may still be processing this information and its potential impact on future approvals.
Indian pharma stocks are currently facing multiple headwinds that are affecting the entire sector. The stronger US dollar is impacting export margins for companies heavily dependent on American markets like Zydus.
Rising raw material costs and global supply chain disruptions are adding to the pressure. Zydus has seen its gross margins slip to around 60% in recent quarters compared to 66% earlier.
The company is investing heavily in research and development with 1,500 scientists and has expanded to 27,000 employees globally. These investments in biosimilars and new products may be pressuring near term profitability.
| Metric | Q2 FY26 | Change |
|---|---|---|
| Revenue | Rs 6,232 crore | +17.47% YoY, -7.38% QoQ |
| Market Cap | Rs 93,800 crore | Current |
| Gross Margin | ~60% | Down from ~66% |
| P/E Ratio | 18.55x | FY25 EPS basis |
In Q2 FY26, Zydus reported revenue of Rs 6,232 crore showing strong year on year growth of 17.47%. However, the quarter on quarter decline of 7.38% has raised some concerns among analysts. The Q4 FY25 profit fell 1% year on year to Rs 1,171 crore amid exceptional items of Rs 219.6 crore.
Despite the current weakness, Zydus has several positive catalysts on the horizon. The company recently announced a partnership with Formycon AG for biosimilar FYB206, which is an alternative to Keytruda for oncology immunotherapy.
Zydus will commercialize this product in the US and Canada with BLA submission imminent. This marks the company’s entry into the North American biosimilar market.
Additionally, the company is planning a potential QIP of Rs 5,000 crore by early 2026. With 428 USFDA approvals since 2003, Zydus has a strong track record. Analysts forecast a 12 month upside to Rs 1,000 plus if US sales momentum continues.
The current decline in Zydus Lifesciences appears to be more technical and sector driven rather than due to company specific bad news.
The stock is facing selling pressure from profit booking after a strong run earlier this year. The technical setup suggests further consolidation in the near term.
However, long term investors may view this as an opportunity given the company’s strong product pipeline and biosimilar expansion plans. The upcoming Q3 results and new product launches will be key catalysts to watch.
Share This Post